malecare®  Men fighting cancer together.  

Prostate Cancer, Support Groups  and Prostate Cancer Treatment

Home | Up | 攝護腺癌 | Espanol | Francais | עברית | Italiano | Portugues | Russian | Site Map | Donate to Malecare   

[Taxotere] [Phenoxodiol]

Taxotere® Evaluated for Treatment of Hormone-Dependent Prostate Cancer.

Researchers from the University of Medicine and Denistry of New Jersey/Robert Wood Johnson Medical School have reported that Taxotere® (docetaxel) is well tolerated and effective in men with PSA progression after completion of local therapy. The details of this phase II study were reported in an advanced publication of the Journal of Clinical Oncology.

Recent studies have suggested that hormone-refractory prostate cancer is sensitive to chemotherapy. However, the use of chemotherapy in the treatment of prostate cancer has historically been met with some resistance because clinical trials failed to document an improvement in survival. Currently, only three drugs, Taxotere®, Emcyt® (estramustine) and mitoxantrone, are FDA-approved for the treatment of prostate cancer. Recent publications suggest that Taxotere® alone or combined with Emcyt® with or without prednisone may be the optimal treatment of hormone-refractory prostate cancer. There is limited experience with the use of chemotherapy in patients with hormone-sensitive disease.  However, this is a logical extension following the demonstration of effectiveness in hormone-refractory disease. Chemotherapy may have many unpleasant side effects but androgen ablation is also not without significant morbidities.

These researchers treated 25 men who had PSA increases of at least 50% for 4 weeks. Prior therapy had consisted of vaccine therapy in 4, mitoxantrone in 10, 13-Cis retinoic acid/interferon alfa in 3 and tamoxifen/P30 protein in 5. The following table summarizes the main findings of this clinical trial.

Table 1: Effect of Taxotere® on Men with Hormone-Dependent PSA Progression

Number of Patients25
Mean age (range)64 years (36-77)
PSA decrease18
PSA progression5
PSA decrease 50% or greater43%
PSA decrease 75% or greater135

These authors reported that Taxotere® had no effect on testosterone levels. They concluded that this study indicated that Taxotere® had an effect on early hormone-sensitive prostate cancer without affecting testosterone levels.

Comments: This is the first or one of the first studies to evaluate chemotherapy in early prostate cancer. It will be of interest to see if this concept evolves into studies of the impact of early chemotherapy on survival and quality of life compared to anti-androgen therapy.

Reference: Goodin S, Medina P, Capanna T, et al. Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer. Journal of Clinical Oncology. 2005;23:

last updated May 2005

[Taxotere] [Phenoxodiol]

What is the Prostate?
Prostate Cancer Diagnosis
Prostate Cancer PSA
Gleason Score
Staging Prostate Cancer
Prostate Carcinoma
Ask your Doctor
DNA Ploidy
Treatment Choices
Best Treatment?
Prostate Surgery Patient Hints
Prostate Cancer Surgery
Choosing A Surgeon
Laparoscopic Prostate Surgery
Radiation IMRT
HIFU for Prostate Cancer
HDR Brachytherapy
Hormone Therapy
Prostate Cancer Cryoablation
Prostate Cancer Chemotherapy
Urinary Bladder
Urinary Incontinence
Urinary Catheter Care
Sperm Banking
Prostate Cancer Diet
Prostate Cancer News
Catalona on Prostate Cancer
Fish Oil & Prostate Cancer
Chondroitin Sulfate
Alternatives for PCa
Prostate Cancer Conference
Prostate Poetry
Prostate Cancer Books
Prostate Cancer Videos
Treatment Story
Kegel Exercises
Combination Therapy
Relaxation & Visualisation

Home | Up | Support Groups | Gay Prostate Cancer | Testicular Cancer | Enlarged Prostate | Male Breast Cancer | Tests for Men | Prostatitis | Erectile Dysfunction | Peyronie's Disease | Enlarged Breasts | Cells and Cancer | African American | Preventing Cancer | Why Support Groups? | About Malecare | Disclaimer/Privacy | New Dad | More on Cancer | Provenge

General comments or questions about prostate cancer, testicular cancer or any other men's cancer:
 Comments about this web site:      
  Website updated on  April 2008
    Copyright © 1998-2008 Malecare, Inc.
a 501(c)3 nonprofit corporation in prostate cancer